AI Article Synopsis
- - Lewy body disease (LBD), also known as Lewy body dementia, is a common but often misdiagnosed neurodegenerative disease due to its similarities with Alzheimer's and Parkinson's diseases.
- - Improving the identification of LBD is crucial for enhancing care and support for both individuals with the condition and their caregivers.
- - Addressing the diagnostic challenges of LBD is a key health goal, as better recognition can lead to more effective treatment and management.
Article Abstract
Despite its high prevalence among neurodegenerative diseases, Lewy body disease (LBD), or Lewy body dementia (LBD), because of its clinical proximity to Alzheimer's and Parkinson's diseases, is often undiagnosed or misdiagnosed. Better identification of this condition, in order to provide better care for sufferers and their carers, is a health objective on which progress is desirable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.revinf.2024.08.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mild behavioral impairment in idiopathic REM sleep behavior disorder and Lewy body disease continuum.
J Neural Transm (Vienna)
January 2025
Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University of College of Medicine, Seoul, Republic of Korea.
To investigate the clinical impact of mild behavioral impairment (MBI) in a predefined cohort with Lewy body disease (LBD) continuum. Eighty-four patients in the LBD continuum participated in this study, including 35 patients with video-polysomnography-confirmed idiopathic REM sleep behavior disorder (iRBD) and 49 clinically established LBD. Evaluations included the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), neuropsychological tests, and MBI Checklist (MBI-C).
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Neurology Department Infanta Leonor Hospital, Madrid, Spain.
Background: biomarkers are essential in order to make a diagnosis with a high level of accuracy in patients with cognitive and behavior complaints. However, molecular imaging biomarkers not always provide an answer in daily clinical practice.
Methods: retrospective and descriptive study in patients with Amyloid PET (APscans) implemented according to rational use of this technic, between January 2019-November 2023 in Neurology Department, Infanta Leonor Hospital, Madrid, Spain.
Biomarkers.
Alzheimers Dement
December 2024
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Background: Many proposed clinical decision support systems (CDSS) require multiple disparate data elements as input, which makes implementation difficult, and furthermore have a black-box nature leading to low interpretability. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is an established modality for the diagnosis of dementia, and a CDSS that uses only an FDG-PET image to produce a reliable and understandable result would ease both of these challenges to clinical application.
Method: A deep variational autoencoder (VAE) was used to extract a latent representation of each image through prior training from FDG-PET brain images (n=2000).
Background: The amplitude of resting-state electroencephalographic (rsEEG) rhythms is a promising neurophysiological biomarker to investigate the abnormalities of oscillatory neurophysiological thalamocortical mechanisms related to the general cortical arousal and vigilance in wakefulness in patients with dementia due to neurodegenerative diseases as Alzheimer's disease (ADD), Parkinson's disease (PDD) and Lewy Body disease (DLB). Here, we tested the hypothesis that the reactivity of posterior rsEEG alpha (about 8-12 Hz) rhythms during the transition from eyes-closed to -open condition may be lower in PDD patients than in DLB patients.
Methods: A Eurasian database provided clinical-demographic-rsEEG datasets in 35 ADD patients, 65 PDD patients, 30 DLB patients, and 25 matched cognitively unimpaired (Healthy) persons.
Biomarkers.
Alzheimers Dement
December 2024
Research Center of Neurology, Moscow, Russian Federation.
Background: Dysfunction of the glymphatic system (GS), a recently discovered brain by-product elimination system, is considered to be one of the pathophysiological mechanisms for common neurodegenerative diseases such as Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and Parkinson's disease (PD). In 2017 a new way to assess the GS was proposed - a diffusion tensor images analysis along perivascular spaces (DTI-ALPS). In our work we evaluated the DTI-ALPS index in groups of patients with AD, DLB, PD and in a comparison group of patients with normal pressure hydrocephalus (NPH).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!